Department of Food, Environmental and Nutritional Sciences (DeFENS), University of Milan, Milan, Italy.
Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, Siena, Italy.
J Enzyme Inhib Med Chem. 2022 Dec;37(1):2382-2394. doi: 10.1080/14756366.2022.2117317.
Inhibition of c-Src is considered one of the most studied approaches to cancer treatment, with several heterocyclic compounds approved during the last 15 years as chemotherapeutic agents. Starting from the biological evaluation of an collection of small molecules, indolinone was selected as the most promising scaffold. In this work, several functionalised indolinones were synthesised and their inhibitory potency and cytotoxic activity were assayed. The pharmacological profile of the most active compounds, supported by molecular modelling studies, revealed that the presence of an amino group increased the affinity towards the ATP-binding site of c-Src. At the same time, bulkier derivatizations seemed to improve the interactions within the enzymatic pocket. Overall, these data represent an early stage towards the optimisation of new, easy-to-be functionalised indolinones as potential c-Src inhibitors.
抑制 c-Src 被认为是癌症治疗中研究最多的方法之一,在过去的 15 年中,有几种杂环化合物被批准作为化疗药物。本研究从对小分子化合物库的生物学评价开始,选择吲唑酮作为最有前途的支架。在这项工作中,合成了几种功能化的吲唑酮,并对它们的抑制活性和细胞毒性进行了检测。药理特性最活跃的化合物的研究,支持分子建模研究,表明氨基的存在增加了对 c-Src 的 ATP 结合位点的亲和力。同时,更大的衍生物似乎改善了酶口袋内的相互作用。总的来说,这些数据代表了优化新型、易于功能化的吲唑酮作为潜在 c-Src 抑制剂的早期阶段。